N-Isoquinolin-3-ylformamide | 64172-28-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: N-Isoquinolin-3-ylformamide
• CAS: 64172-28-7
• 化学式: C₁₀H₈N₂O
• 分子量: 172.18
• InChiKey: HXUYXWSQRYLPIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-Isoquinolin-3-ylformamide 、 2,4,6-三甲基苯磺酰羟胺 以82%的产率得到
  参考文献：
  名称：

  TAMURA Y.; IWAISAKI M.; MIKI Y.; IKEDA M., HETEROCYCLES, 1977, 6, NO 7, 949-952

  摘要：

  DOI：

文献信息

• [EN] ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS D'ISOQUINOLÉINE POUR LE TRAITEMENT DU CANCER
  申请人：GENENTECH INC

  公开号：WO2020072627A1

  公开（公告）日：2020-04-09

  3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.

  描述了化学式（I）的3-羰基氨基异喹啉化合物及其变体，以及它们作为HPK1（造血激酶1）抑制剂的用途。这些化合物可用于治疗HPK1依赖性疾病并增强免疫反应。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备3-羰基氨基异喹啉化合物的方法。
• Epoxycarboxamide compound, azide compound, and amino alcohol compound, and process for preparing alpha-keto amide compound using them
  申请人：Seikagaku Corporation

  公开号：US20030153788A1

  公开（公告）日：2003-08-14

  The present invention is to provide manufacturing intermediates which can be led to useful &agr;-ketoamide compounds having protease-inhibiting activity extremely economically and stereoselectively, and to provide epoxycarboxamide compounds, azide compounds and amino alcohol compounds represented by the following formulae: 1 wherein R 1 and R 2 each represents alkyl group, alkenyl group, aromatic hydrocarbon group or heterocyclic group; R 3 represents alkyl group, alkenyl group, aromatic hydrocarbon group, heterocyclic group, R 6 —O— or R 7 —N(R 8 )—; where R 6 represents alkyl group, alkenyl group, aromatic hydrocarbon group or heterocyclic group; R 7 and R 8 each represents hydrogen atom, alkyl group, alkenyl group, aromatic hydrocarbon group or heterocyclic group, and, R 4 and R 5 represent the same groups as R 7 and R 8 , respectively, and R 4 and R 5 optionally form a ring together; and X represents —O— or —N(R 9 )—, where R 9 represents hydrogen atom or alkyl group, and X optionally forms a ring together with R 4 or R 5 , and processes for preparing &agr;-keto amide compound using the same.

  本发明旨在提供制造中间体，以极其经济和立体选择性地导向有蛋白酶抑制活性的有用α-酮酰胺化合物，并提供由以下式表示的环氧羧酰胺化合物，叠氮化合物和氨基醇化合物：其中R1和R2分别表示烷基，烯基，芳香族烃基或杂环基；R3表示烷基，烯基，芳香族烃基，杂环基，R6-O-或R7-N（R8）-；其中R6表示烷基，烯基，芳香族烃基或杂环基；R7和R8分别表示氢原子，烷基，烯基，芳香族烃基或杂环基，而R4和R5分别表示与R7和R8相同的基团，R4和R5可选择性地共同形成环；X表示-O-或-N（R9）-，其中R9表示氢原子或烷基，X可选择性地与R4或R5共同形成环，以及使用它们制备α-酮酰胺化合物的方法。
• Aza-Substituted Spiro Derivatives
  申请人：Jitsuoka Makoto

  公开号：US20090258871A1

  公开（公告）日：2009-10-15

  A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH 2 )m 2 -, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R 6 , R 7 and R 8 independently represent a lower alkyl group or the like].

  提供以下式子（I）的化合物或其药学上可接受的盐：[其中X、Y、Z和W各自独立地表示甲基基团或氮原子，前提是当X、Y、Z和W全部为甲基基团时；A表示—O—或类似物，B表示—C（O）—或类似物，D表示—（CH2）m2-、—O—或类似物，m2表示0或1；Q表示甲基基团或氮原子；R表示由以下式子（II-1）表示的基团（其中R6、R7和R8各自独立地表示较低的烷基基团或类似物）。
• Carbamoyl-Substituted Spiro Derivative
  申请人：Jitsuoka Makoto

  公开号：US20080171753A1

  公开（公告）日：2008-07-17

  A compound represented by, e.g. the formula (I): [wherein X, Y, Z, and W each independently represent optionally substituted methine; A, B, and D each independently represent —C(O)—, etc.; Q represents a methine or a nitrogen; and R represents the formula (II-1), optionally substituted with lower alkyl, etc.; (wherein R 6 represents a lower alkyl, etc; and R 7 and R 8 each independently represents a lower alkyl, etc.)] or a pharmaceutically acceptable salt of the compound. The compounds and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor. They are useful in the prevention or treatment of metabolic diseases, circulatory diseases, or neurotic diseases.

  化合物的化学式为(I):[其中X、Y、Z和W各自独立地表示可选择性取代的甲烷基；A、B和D各自独立地表示—C(O)—等；Q表示甲烷基或氮；R表示化学式(II-1)，可选择性地取代较低的烷基等；(其中R6表示较低的烷基等；R7和R8各自独立地表示较低的烷基等)]或其药学上可接受的盐。这些化合物和盐对组胺H3受体具有拮抗活性或反向激动活性。它们可用于预防或治疗代谢性疾病、循环系统疾病或神经疾病。
• Quinazoline Derivative
  申请人：Mizutani Takashi

  公开号：US20080275069A1

  公开（公告）日：2008-11-06

  This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (I) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1代表较低的烷基等；R2和R3相同或不同，分别代表氢原子等；R4代表式（I）的取代基等；X1代表NH、O或S；Y代表N或C；Ar是由芳基衍生的二价取代基等，通过去除其中的两个氢原子而得到；环A表示5-或6-成员杂芳基基团；这些化合物具有组胺H3受体拮抗作用或组胺H3受体反向激动剂作用，并且对于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病是有用的。